AdaptHealth Corp.

AdaptHealth Corp.(AHCO)股票分析

$6.250

-0.079 (-1.26%)收盤時

Loading chart…
最高
6.380
開盤
6.320
成交量加權均價
6.28
成交量
1.82M
市值
1.31B
最低
6.200
成交金額
11.45M
企業價值/稅息折舊攤銷前利潤(TTM)
6.25

AdaptHealth Corp. and subsidiaries are engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under three segments that align with its product categories: Sleep Health, Respiratory Health, and Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Wellness at Home segment provides home medical equipment and services to patients in their homes, including those who have been discharged from acute care and other facilities.

AI 分析 of AdaptHealth Corp. (AHCO)

持有

Adapthealth Corp is not a strong buy right now due to significant recent losses and a declining sales forecast. The current price is $6.06, and the stock has a high RSI of 77.713, indicating it may be overbought. Additionally, the forward P/E ratio is 7.776, which suggests it may be undervalued, but the company's recent earnings report showed a loss of $1.07 per share, far below expectations, leading to a 47% drop in stock price. The main risk is the declining cash flow projections, now expected between $80 million and $120 million, down from previous estimates, which could hinder future growth.

估值指標

AdaptHealth Corp.(AHCO)目前預期本益比為 7.78,5 年平均預期本益比為 12.46。

預期本益比

低估
5 年均值 P/E
12.46
目前P/E
7.78
高估
16.86
低估
8.06

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
5.94
目前EV/EBITDA
6.25
高估
7.08
低估
4.80

預期股價營收比

低估
5 年均值 P/S
0.53
目前P/S
0.28
高估
0.76
低估
0.29

Alphio AI 對 AHCO 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%AHCO

$9.12

情境價格

基

基準

基準 · 50%AHCO

$8.64

情境價格

悲

悲觀

悲觀 · 25%AHCO

$7.24

情境價格

持有 AHCO 的大戶

D

Deerfield Management Company, L.P.

+ 持有AHCO

-8.23%

3個月報酬率

事件時間軸

2026-09-08 (ET)

16:30:00

AdaptHealth Appoints Harriss T. Currie as CFO

2026-08-04 (ET)

12:00:00

Major Averages Surge Again, Tech Shares Lead Gains

07:30:00

Company Revises FY2026 Financial Guidance to $2.85B-$2.89B

07:30:00

AdaptHealth Reports Q2 Revenue of $740.3M, Lowers Full-Year Outlook

2026-07-20 (ET)

17:00:00

Cardinal Health Acquires AdaptHealth and Strive Medical for $360M

資訊

AHCO 常見問題 —— 由 Alphio AI 解答

AdaptHealth Corp. and subsidiaries are engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under three segments that align with its product categories: Sleep Health, Respiratory Health, and Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Wellness at Home segment provides home medical equipment and services to patients in their homes, including those who have been discharged from acute care and other facilities. It operates in the Healthcare sector (SERVICES-HOME HEALTH CARE SERVICES industry).

Adapthealth Corp is not a strong buy right now due to significant recent losses and a declining sales forecast. The current price is $6.06, and the stock has a high RSI of 77.713, indicating it may be overbought. Additionally, the forward P/E ratio is 7.776, which suggests it may be undervalued, but the company's recent earnings report showed a loss of $1.07 per share, far below expectations, leading to a 47% drop in stock price. The main risk is the declining cash flow projections, now expected between $80 million and $120 million, down from previous estimates, which could hinder future growth.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易